Johnson & Johnson Stock News

Johnson & Johnson is regaining momentum with strong growth in its Innovative Medicine and MedTech segments, driven by new products and strategic acquisitions. The company's robust financials, including a triple-A credit rating and significant cash reserves, position it well for sustained growth and reduced legal risks. Despite past underperformance, the company offers a reliable 3.1% dividend a...

JNJ bulls often praise its dividends - rightfully. However, the above-average yield and remarkable dividend record understate the attractiveness. Investors should focus on total shareholder returns, which include dividends but also other factors such as EPS growth and buybacks.

While Eli Lilly & Co (NYSE: LLY) has captured the spotlight in 2024 due to the soaring demand for its weight-loss drug, investors may want to turn their attention to another pharmaceutical giant: Johnson & Johnson (NYSE: JNJ).

I will demonstrate how you could allocate the amount of $100,000 by following the current composition of The Dividend Income Accelerator Portfolio, effectively balancing dividend income and dividend growth. Potential benefits of its implementation are a reduced portfolio risk level, stable dividend income, strong potential for dividend growth and capital appreciation, and elevated chances of an...

Eli Lilly's weight loss drugs are pushing the company's market cap toward $1 trillion. Johnson & Johnson is the global leader in drug sales, but its market cap is under $400 billion.

Johnson & Johnson (JNJ) on Tuesday announced Food and Drug Administration (FDA) approval of a two-drug, chemotherapy-free treatment plan for certain types of lung cancer, along with an acquisition expanding its offerings to treat heart disease.

Blue chip stocks dominate the list of hedge funds' most popular equity investments.

The FDA has approved Rybrevant plus Lazcluze in the U.S. for the treatment of patients with non-small cell lung cancer.